Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19

PURPOSE: To assess the outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) for rhino-orbital-cerebral-mucormycosis (ROCM) post-COVID-19, as an adjuvant to standard systemic antifungal therapy. METHODS: In this prospective cohort study involving ROCM patients with clinical/radiological orbi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shakrawal, Jyoti, Sharma, Vidhu, Goyal, Amit, Kumar, Deepak, Meena, Seema, Tiwari, Sarbesh, Jain, Vidhi, Elhence, Poonam, Soni, Kapil, Choudhury, Bikram, Bhatnagar, Kavita, Garg, Mahendra Kumar, Misra, Sanjeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702621/
https://www.ncbi.nlm.nih.gov/pubmed/36427099
http://dx.doi.org/10.1007/s10792-022-02591-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702621/
https://www.ncbi.nlm.nih.gov/pubmed/36427099
http://dx.doi.org/10.1007/s10792-022-02591-0

Ejemplares similares